Latest news with #TIDESUSA
Fibre2Fashion
28-05-2025
- Business
- Fibre2Fashion
US' DuPont launches AmberChrom TQ1 for biopharma applications
DuPont has expanded its bioprocessing portfolio with the launch of DuPont AmberChrom TQ1 chromatography resin for the purification of oligonucleotides and peptides in support of a wide-range of biopharma applications. DuPont has launched AmberChrom TQ1 chromatography resin for purifying oligonucleotides and peptides, expanding its bioprocessing portfolio. The resin offers high capacity, throughput, and purity with low pressure, suitable for all scales. Internal studies using real-world drug feeds validated its performance across development stages. 'The introduction of DuPont AmberChrom TQ1 chromatography resin supports the accelerated development and commercialization of oligonucleotide and peptide therapeutics,' said Shane Kendra, Global Bioprocessing Market Leader for DuPont Water Solutions. 'In addition to expanding our capabilities, this new anion exchange chromatography resin offers exceptional performance, setting a new standard in this product class and creating new opportunities in high growth therapy areas.' The new agarose-based chromatography resin offers increased loading capacity, higher throughput, and requires less pressure than comparable competing products within the same class. These characteristics make DuPont AmberChrom TQ1 chromatography resin an excellent choice for high resolution separations and polishing, offering high purity fractions in biomolecule purifications and the separation of closely-related impurities from target molecules. Its low-pressure build-up, combined with high-yield and purity for peptides and both DMT-Off and DMT-On oligonucleotides, makes the resin suitable for use in benchtop and large-scale commercial purifications. To support the introduction of the resin, DuPont has published comprehensive internal application studies that used real-world drug feeds to validate performance characteristics; this documentation can also assist with the integration of the product into processes at every phase from drug discovery through commercialization. 'Further expansion of DuPont's bioprocessing portfolio reflects our commitment to providing a comprehensive one-stop shop for the purification and polishing of oligonucleotides and peptides,' said Kendra. 'Our technical teams and scientists are continually collaborating with customers to design efficient bioprocessing solutions for every stage of the drug development journey.' DuPont AmberChrom TQ1 chromatography resin can be used in combination with existing AmberChrom XT and CG chromatography resins to purify various oligonucleotide feeds, or for the crude purification of peptide feeds in preparation for reverse phase chromatography. DuPont introduced the new chromatography resin to the market during TIDES USA—a conference dedicated to accelerating oligonucleotide and peptide innovations. Hadi Fares, Ph.D, a bioprocessing application scientist with DuPont, presented application studies to demonstrate the performance capabilities of DuPont AmberChrom TQ1 chromatography resin, and how it complements existing resins within the DuPont bioprocessing portfolio. On June 19, 2025, DuPont will host an educational webinar discussing the capabilities of DuPont AmberChrom TQ1 chromatography resin and how its loading capacity and purification efficacy can enhance purification of oligonucleotides and peptides. As a global market leader in adsorbents and ion exchange resins with over 80 years of experience, DuPont bioprocessing solutions can accelerate and enhance the discovery and production of small molecule synthetics, oligonucleotides, and peptides, as well as diagnostics, by enabling complicated separations that help companies achieve their vision to manage and treat diseases. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged. Fibre2Fashion News Desk (HU)
Yahoo
19-05-2025
- Business
- Yahoo
Fujifilm Validates Cancer Cell-Targeting Potential of Peptide Oligonucleotide Conjugates with Novel Cyclic Peptides
Research highlights to be presented at TIDES USA 2025 TOKYO, May 19, 2025--(BUSINESS WIRE)--FUJIFILM Corporation announces the successful validation of the cancer cell-targeting potential of its peptide-oligonucleotide conjugates. This validation resulted from combining oligonucleotides with cyclic peptides developed from Fujifilm's proprietary peptide library, which contains trillions of variants. This research achievement will be presented at TIDES USA, an exhibition to be held from May 19 to 22, 2025, in San Diego (poster number: 35). Cyclic peptides, including those containing unnatural amino acids, are emerging as a promising new modality in drug discovery due to their unique and favorable properties, including high binding affinity and specificity, improved tissue permeability, and synthetic versatility. Peptide-oligonucleotide conjugation addresses delivery challenges associated with oligonucleotide-based therapies by utilizing the excellent delivery properties of peptides and have been actively researched. Leveraging its large peptide library constructed with mRNA display technology, and structural optimization techniques, Fujifilm has developed a proprietary cyclic peptide that binds strongly to integrins overexpressed on the surface of cancer cells, with a low dissociation constant (KD) of 1.6 nM. Utilizing chemical modification methods Fujifilm can successfully synthesize the peptide-oligonucleotide conjugate at high yield. Uptake of these peptide-oligonucleotide conjugates by cancer cells is higher compared to uptake of the non-conjugated oligonucleotide, demonstrating the peptide-oligonucleotide conjugate's ability to selectively accumulate in cancer cells. Fujifilm is expanding its drug discovery services for peptide therapeutics globally, providing a wide range of contract research services focusing on peptide discovery, high-throughput screening, and structural optimization. Fujifilm's one-stop comprehensive service includes peptide chemical synthesis and target protein expression and purification to meet diverse research demands. Fujifilm is committed to driving research and development that fosters technological innovation in the healthcare field, leveraging the ability of cyclic peptides to regulate cellular functions and their specific molecular recognition capabilities, contributing to the advancement of pharmaceutical development of peptide therapeutics. For more information please visit: Discovery Service of Diverse and High-Affinity Cyclic Peptides View source version on Contacts Media Contact Christine JackmanFUJIFILM Holdings America CorporationE-mail: Tel: +1-914-261-4959 Megan AugustineFUJIFILM Holdings America CorporationE-mail: Other Contact CRO Business Development OfficeFUJIFILM CorporationE-mail: dge-CRO-inq@ Sign in to access your portfolio
Business Wire
19-05-2025
- Business
- Business Wire
Fujifilm Validates Cancer Cell-Targeting Potential of Peptide Oligonucleotide Conjugates with Novel Cyclic Peptides
TOKYO--(BUSINESS WIRE)--FUJIFILM Corporation announces the successful validation of the cancer cell-targeting potential of its peptide-oligonucleotide conjugates. This validation resulted from combining oligonucleotides with cyclic peptides developed from Fujifilm's proprietary peptide library, which contains trillions of variants. This research achievement will be presented at TIDES USA, an exhibition to be held from May 19 to 22, 2025, in San Diego (poster number: 35). Cyclic peptides, including those containing unnatural amino acids, are emerging as a promising new modality in drug discovery due to their unique and favorable properties, including high binding affinity and specificity, improved tissue permeability, and synthetic versatility. Peptide-oligonucleotide conjugation addresses delivery challenges associated with oligonucleotide-based therapies by utilizing the excellent delivery properties of peptides and have been actively researched. Leveraging its large peptide library constructed with mRNA display technology, and structural optimization techniques, Fujifilm has developed a proprietary cyclic peptide that binds strongly to integrins overexpressed on the surface of cancer cells, with a low dissociation constant (K D) of 1.6 nM. Utilizing chemical modification methods Fujifilm can successfully synthesize the peptide-oligonucleotide conjugate at high yield. Uptake of these peptide-oligonucleotide conjugates by cancer cells is higher compared to uptake of the non-conjugated oligonucleotide, demonstrating the peptide-oligonucleotide conjugate's ability to selectively accumulate in cancer cells. Fujifilm is expanding its drug discovery services for peptide therapeutics globally, providing a wide range of contract research services focusing on peptide discovery, high-throughput screening, and structural optimization. Fujifilm's one-stop comprehensive service includes peptide chemical synthesis and target protein expression and purification to meet diverse research demands. Fujifilm is committed to driving research and development that fosters technological innovation in the healthcare field, leveraging the ability of cyclic peptides to regulate cellular functions and their specific molecular recognition capabilities, contributing to the advancement of pharmaceutical development of peptide therapeutics.
Business Wire
15-05-2025
- Business
- Business Wire
EnPlusOne Biosciences To Present New Data at TIDES USA
WATERTOWN, Mass.--(BUSINESS WIRE)--EnPlusOne Biosciences, Inc., a biotechnology company pioneering enzymatic solutions for RNA manufacturing, will present new data from its proprietary ezRNA™ platform at TIDES USA, the leading conference focused on oligonucleotide and peptide therapeutics, taking place May 19-22 in San Diego at the Manchester Grand Hyatt. 'Our enzymatic approach removes long-standing barriers in RNA manufacturing that center around the use and disposal of hazardous organic solvents,' said Mr. Ahlstedt. 'We're excited to show the industry what scalable enzymatic synthesis looks like." Share In a featured talk titled 'Solving the Scale Problem: Template-independent Enzymatic Synthesis of siRNA Oligonucleotides,' EnPlusOne's Chief Operating Officer and co-founder Dan Ahlstedt will share recent advances in the company's aqueous-based, template-free RNA synthesis technology. The presentation will highlight the platform's ability to synthesize complex and fully-modified siRNA while offering the benefits of improved scalability, cost, and sustainability compared with traditional phosphoramidite chemistry. 'Our enzymatic approach removes long-standing barriers in RNA manufacturing that center around the use and disposal of hazardous organic solvents,' said Mr. Ahlstedt. 'We're excited to show the industry what scalable enzymatic synthesis looks like in practice and how it opens the door for broader therapeutic applications.' The presentation will also preview a new independent facility cost comparison study revealing that EnPlusOne's enzymatic process can reduce capital expenditures by at least 20% versus traditional RNA synthetic methods, while achieving comparable throughput and significantly reducing solvent and hazardous waste generation. This presentation builds on recent momentum for EnPlusOne, including the appointment of Clare Murray, PhD, as CEO to lead the company's commercialization strategy, and a recent $10 million financing round aimed at expanding strategic partnerships and scaling up synthesis capabilities. Dr. Murray and Mr. Ahlstedt will be onsite at TIDES USA to meet with current and prospective partners. About EnPlusOne Biosciences EnPlusOne is enabling the future of RNA therapeutics. Its ezRNA™ platform is a next-generation enzymatic synthesis technology that leverages water-based, template-free reactions to manufacture high-quality RNA at scale. Capable of incorporating a wide range of natural and modified nucleotides, ezRNA™ is designed to meet the evolving needs of RNA therapeutic developers. Learn more at
Yahoo
15-05-2025
- Business
- Yahoo
EnPlusOne Biosciences To Present New Data at TIDES USA
Showcases Scalable, Sustainable Enzymatic RNA Synthesis Platform as well as an Independent Cost Analysis at Industry's Leading Oligonucleotide Conference WATERTOWN, Mass., May 15, 2025--(BUSINESS WIRE)--EnPlusOne Biosciences, Inc., a biotechnology company pioneering enzymatic solutions for RNA manufacturing, will present new data from its proprietary ezRNA™ platform at TIDES USA, the leading conference focused on oligonucleotide and peptide therapeutics, taking place May 19-22 in San Diego at the Manchester Grand Hyatt. In a featured talk titled "Solving the Scale Problem: Template-independent Enzymatic Synthesis of siRNA Oligonucleotides," EnPlusOne's Chief Operating Officer and co-founder Dan Ahlstedt will share recent advances in the company's aqueous-based, template-free RNA synthesis technology. The presentation will highlight the platform's ability to synthesize complex and fully-modified siRNA while offering the benefits of improved scalability, cost, and sustainability compared with traditional phosphoramidite chemistry. "Our enzymatic approach removes long-standing barriers in RNA manufacturing that center around the use and disposal of hazardous organic solvents," said Mr. Ahlstedt. "We're excited to show the industry what scalable enzymatic synthesis looks like in practice and how it opens the door for broader therapeutic applications." The presentation will also preview a new independent facility cost comparison study revealing that EnPlusOne's enzymatic process can reduce capital expenditures by at least 20% versus traditional RNA synthetic methods, while achieving comparable throughput and significantly reducing solvent and hazardous waste generation. This presentation builds on recent momentum for EnPlusOne, including the appointment of Clare Murray, PhD, as CEO to lead the company's commercialization strategy, and a recent $10 million financing round aimed at expanding strategic partnerships and scaling up synthesis capabilities. Dr. Murray and Mr. Ahlstedt will be onsite at TIDES USA to meet with current and prospective partners. About EnPlusOne Biosciences EnPlusOne is enabling the future of RNA therapeutics. Its ezRNA™ platform is a next-generation enzymatic synthesis technology that leverages water-based, template-free reactions to manufacture high-quality RNA at scale. Capable of incorporating a wide range of natural and modified nucleotides, ezRNA™ is designed to meet the evolving needs of RNA therapeutic developers. Learn more at View source version on Contacts Mary T. ConwayConway Communicationsmtconway@ 617-407-8778
